Evidence map›Paper›PMID 42225988›Full record

ArticleNature medicine2026

SEZ6-targeting antibody-drug conjugate ABBV-706 in advanced small cell lung cancer and solid tumors: a phase 1 trial.

Lauren Averett Byers, Byoung Chul Cho, Alissa J Cooper, Anne C Chiang, Ji-Youn Han, Muhammad Furqan, Afshin Dowlati, Daniel Morgensztern, Kyriakos P Papadopoulos, Noura J Choudhury and 21 more

Erratum issuedAbstract readClinical Trial, Phase IMulticenter Study
PubMed Full text at PMC Publisher
In one paragraph

Article in Nature medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed.

  1. Review
  2. Review
  3. Review
  4. Review
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

31 authors.

Lauren Averett ByersThe University of Texas MD Anderson Cancer Center, Houston, TX, USA. lbyers@mdanderson.org.ORCID http://orcid.org/0000-0002-0780-2677
Byoung Chul ChoDivision of Medical Oncology, Yonsei University College of Medicine, Yonsei Cancer Center, Seoul, Republic of Korea.ORCID http://orcid.org/0000-0002-5562-270X
Alissa J CooperDepartment of Thoracic Oncology, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
Anne C ChiangYale School of Medicine, New Haven, CT, USA.ORCID http://orcid.org/0000-0002-2111-4694
Ji-Youn HanNational Cancer Center, Gyeonggi-do, Republic of Korea.ORCID http://orcid.org/0000-0001-5033-0006
Muhammad FurqanUniversity of Iowa Holden Comprehensive Cancer Center, Iowa City, IA, USA.
Afshin DowlatiUniversity Hospitals Seidman Cancer Center and Case Western Reserve University, Cleveland, OH, USA.
Daniel MorgenszternWashington University School of Medicine, St. Louis, MO, USA.
Kyriakos P PapadopoulosSTART San Antonio, San Antonio, TX, USA.
Noura J ChoudhuryDepartment of Medicine, University of Chicago, Chicago, IL, USA.ORCID http://orcid.org/0000-0002-5980-4973
María VieitoDepartment of Medical Oncology, Vall d'Hebron Barcelona Hospital Campus, Barcelona, Spain.
Jair BarJusidman Cancer Center, Sheba Medical Center, Ramat Gan, Israel.ORCID http://orcid.org/0000-0002-1224-3646
Joo-Hang KimDepartment of Internal Medicine, CHA Bundang Medical Center, CHA University, Seongnam, Republic of Korea.
Wallace AkerleyDivision of Medical Oncology, Huntsman Cancer Institute, University of Utah, Salt Lake City, UT, USA.
Tae Min KimDepartment of Internal Medicine, Seoul National University Hospital, Seoul National University College of Medicine, Seoul, Republic of Korea.ORCID http://orcid.org/0000-0001-6145-4426
Young-Chul KimDepartment of Internal Medicine, Chonnam National University Medical School, and Chonnam National University Hwasun Hospital, Jeonnam, Republic of Korea.ORCID http://orcid.org/0000-0001-7019-7687
Luis Paz-AresHospital Universitario 12 de Octubre and Universidad Complutense, Madrid, Spain.ORCID http://orcid.org/0000-0002-1947-3364
Myung-Ju AhnSection of Hematology-Oncology, Department of Medicine, Hanyang University Medical Center, Hanyang University, Seoul, Republic of Korea.ORCID http://orcid.org/0000-0002-5740-9654
Hiroshi YokouchiNational Hospital Organization Hokkaido Cancer Center, Sapporo, Japan.ORCID http://orcid.org/0000-0001-5964-0051
Darius MeimanAbbVie Inc., North Chicago, IL, USA.
Wijith MunasingheAbbVie Inc., North Chicago, IL, USA.
Oluwadamilola OgunyankinAbbVie Inc., North Chicago, IL, USA.
Nadine JahchanAbbVie Inc., North Chicago, IL, USA.
Song WangAbbVie Inc., North Chicago, IL, USA.
Cristiano FerliniAbbVie Inc., North Chicago, IL, USA.
Randy R RobinsonAbbVie Inc., North Chicago, IL, USA.ORCID http://orcid.org/0000-0002-9503-1111
Frederick J KohlhappAbbVie Inc., North Chicago, IL, USA.
Tammy PalenskiAbbVie Inc., North Chicago, IL, USA.
Guillermo RivellAbbVie Inc., North Chicago, IL, USA.
Pooja HingoraniAbbVie Inc., North Chicago, IL, USA.
Sreenivasa ChandanaSTART Midwest, Grand Rapids, MI, USA.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Seizure-related homolog 6 (SEZ6) is expressed in small cell lung cancer (SCLC) and neuroendocrine neoplasms. In an open label, phase 1 trial, ABBV-706, an antibody-drug conjugate with a SEZ6-directed antibody linked to topoisomerase-1 inhibitor (Top1i), was administered intravenously every 3 weeks (Q3W) to 288 patients with advanced solid tumors; 240 received monotherapy, including 124 with relapsed/refractory (R/R) SCLC. Primary objectives of dose escalation (part 1, advanced solid tumors), dose optimization and expansion (part 2, R/R SCLC only) and dose expansion (part 4, central nervous system tumors and high-grade neuroendocrine neoplasms only) were to evaluate the safety, tolerability, pharmacokinetics (PK), immunogenicity and antitumor activity of ABBV-706 monotherapy and, from parts 1 and 2, to determine the recommended phase 2 dose (RP2D) of ABBV-706 in R/R SCLC. In the monotherapy cohort (N = 240), the most common treatment-related adverse events (TRAEs) at any grade were anemia (61%) and fatigue (38%). Grade 3 or higher TRAEs occurred in 61% of patients and were dose dependent (39% at 1.8 mg kg

Indexed as

ImmunoconjugatesLung NeoplasmsSmall Cell Lung CarcinomaAdultAgedAged, 80 and overFemaleHumansMaleMiddle AgedTopoisomerase I InhibitorsImmunoconjugatesTopoisomerase I Inhibitors

Identifiers

PMID42225988
PMCPMC13472869

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.